NCT00074178View on ClinicalTrials.gov

Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 31, 2000

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions
Lymphoma
Interventions
BIOLOGICAL

filgrastim

BIOLOGICAL

pegfilgrastim

DRUG

cyclophosphamide

DRUG

cytarabine

DRUG

dexamethasone

DRUG

etoposide phosphate

DRUG

methotrexate

Trial Locations (1)

97239-3098

Oregon Health & Science University Cancer Institute, Portland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

OHSU Knight Cancer Institute

OTHER

NCT00074178 - Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma | Biotech Hunter | Biotech Hunter